Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Share this content:
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Sponsors and Collaborators
M.D. Anderson Cancer Center
Novartis

Contact
Nizar M. Tannir, MD, FACP
713-792-2830

Principal Investigator
Nizar M. Tannir, MD, FACP, UT MD Anderson Cancer Center

ClinicalTrials.gov Identifier
NCT01185366

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters